LONDON (Reuters) - Europe set out plans to boost research into the neglected area of antibiotics on Thursday by promising to accelerate approval of new drugs, while ensuring adequate prices for their makers and promoting industry-wide R&D.
Multi-drug resistant bacteria, or so-called superbugs, are a growing threat across Europe, with rates of drug resistance in one type of bacteria reaching 50 percent in the worst-hit countries, according to health officials. But the medicine chest for new antibiotics is practically empty, following a decision by many large drug makers to exit what has become an unprofitable area of research.
EDIT
"We need to declare a war -- a war against these bacteria," the ECDC's director Marc Sprenger told Reuters. Sprenger said that across Europe rates of resistance to last-line antibiotics by a bacteria called Klebsiella pneumoniae had more than doubled to 15 percent by 2010 from around 7 percent five years ago.
"What's even more worrying is that there's a great diversity among different countries in Europe -- and some countries have resistance of almost 50 percent," he said. K. pneumoniae is a common cause of pneumonia, urinary tract, and bloodstream infections in hospital patients. The superbug form is resistant even to a class of medicines called carbapenems, the most powerful known antibiotics, which are usually reserved by doctors as a last line of defense.
EDIT
http://www.baltimoresun.com/health/sns-rt-us-antibiotic-superbugs-europetre7ag0va-20111117,0,6666257.story